C
Christina M. Nagle
Researcher at QIMR Berghofer Medical Research Institute
Publications - 99
Citations - 4376
Christina M. Nagle is an academic researcher from QIMR Berghofer Medical Research Institute. The author has contributed to research in topics: Ovarian cancer & Population. The author has an hindex of 32, co-authored 99 publications receiving 3702 citations. Previous affiliations of Christina M. Nagle include University of Queensland & Royal Brisbane and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
Celeste Leigh Pearce,Claire Templeman,Mary Anne Rossing,Alice Lee,Aimee M. Near,Penelope M. Webb,Christina M. Nagle,Jennifer A. Doherty,Kara L. Cushing-Haugen,Kristine G. Wicklund,Jenny Chang-Claude,Rebecca Hein,Rebecca Hein,Galina Lurie,Lynne R. Wilkens,Michael E. Carney,Marc T. Goodman,Kirsten B. Moysich,Susanne K. Kjaer,Estrid Høgdall,Allan Jensen,Ellen L. Goode,Brooke L. Fridley,Melissa C. Larson,Joellen M. Schildkraut,Rachel T. Palmieri,Daniel W. Cramer,Kathryn L. Terry,Allison F. Vitonis,Linda J. Titus,Argyrios Ziogas,Wendy Brewster,Hoda Anton-Culver,A Gentry-Maharaj,Susan J. Ramus,Susan J. Ramus,A. Rebecca Anderson,Doerthe Brueggmann,Doerthe Brueggmann,Peter A. Fasching,Peter A. Fasching,Simon A. Gayther,Simon A. Gayther,David G. Huntsman,Usha Menon,Roberta B. Ness,Malcolm C. Pike,Malcolm C. Pike,Harvey A. Risch,Anna H. Wu,Andrew Berchuck +50 more
TL;DR: In this paper, the association between self-reported endometriosis and risk of ovarian cancer was found to be a risk factor for epithelial ovarian cancer; however, whether this risk extends to all invasive histological subtypes or borderline tumours is not clear.
Journal ArticleDOI
Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.
TL;DR: On balance chronic inflammation does not play a major role in the development of ovarian cancer, and regular use of aspirin and other nonsteroidal anti‐inflammatory drugs was inversely associated with risk of LMP mucinous ovarian tumours only.
Journal ArticleDOI
Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium
Catherine M. Olsen,Christina M. Nagle,David C. Whiteman,Roberta B. Ness,Celeste Leigh Pearce,Malcolm C. Pike,Malcolm C. Pike,Mary Anne Rossing,Kathryn L. Terry,Anna H. Wu,Harvey A. Risch,Herbert Yu,Jennifer A. Doherty,Jenny Chang-Claude,Rebecca Hein,Stefan Nickels,Shan Wang-Gohrke,Marc T. Goodman,Michael E. Carney,Rayna K. Matsuno,Galina Lurie,Kirsten B. Moysich,Susanne K. Kjaer,Allan Jensen,Estrid Høgdall,Ellen L. Goode,Brooke L. Fridley,Robert A. Vierkant,Melissa C. Larson,Joellen M. Schildkraut,Cathrine Hoyo,Patricia G. Moorman,Rachel Palmieri Weber,Daniel W. Cramer,Allison F. Vitonis,Elisa V. Bandera,Sara H. Olson,Lorna Rodriguez-Rodriguez,Melony King,Louise A. Brinton,Hannah P. Yang,Montserrat Garcia-Closas,Jolanta Lissowska,Hoda Anton-Culver,Argyrios Ziogas,Simon A. Gayther,Susan J. Ramus,Usha Menon,Aleksandra Gentry-Maharaj,Penelope M. Webb +49 more
TL;DR: Obesity appears to increase risk of the less common histological subtypes of ovarian cancer, it does not increaserisk of high-grade invasive serous cancers, and reducing BMI is therefore unlikely to prevent the majority of Ovarian Cancer Association Consortium deaths.
Journal ArticleDOI
Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium
Britton Trabert,Roberta B. Ness,Wei-Hsuan Lo-Ciganic,Megan A. Murphy,Ellen L. Goode,Elizabeth M. Poole,Louise A. Brinton,Penelope M. Webb,Christina M. Nagle,Susan J. Jordan,Harvey A. Risch,Mary Anne Rossing,Jennifer A. Doherty,Jennifer A. Doherty,Marc T. Goodman,Galina Lurie,Susanne K. Kjaer,Estrid Høgdall,Allan Jensen,Daniel W. Cramer,Kathryn L. Terry,Allison F. Vitonis,Elisa V. Bandera,Sara H. Olson,Melony King,Urmila Chandran,Hoda Anton-Culver,Argyrios Ziogas,Usha Menon,Simon A. Gayther,Susan J. Ramus,Aleksandra Gentry-Maharaj,Anna H. Wu,Celeste Leigh Pearce,Malcolm C. Pike,Andrew Berchuck,Joellen M. Schildkraut,Nicolas Wentzensen +37 more
TL;DR: It is suggested that the same aspirin regimen proven to protect against cardiovascular events and several cancers could reduce the risk of ovarian cancer 20% to 34% depending on frequency and dose of use.
Journal ArticleDOI
Obesity and ovarian cancer survival: a systematic review and meta-analysis.
TL;DR: Women with ovarian cancer who are obese appear to have slightly worse survival than non-obese women, but there is a large amount of inter-study variation, which means that no solid conclusions can be drawn.